University Hospitals Cleveland Medical Center (USA)
The Methodist Hospital System (USA)
Inventor
Wilson, David L.
Hoori, Ammar
Wu, Hao
Gilkeson, Robert C.
Rajagopalan, Sanjay
Al-Kindi, Sadeer
Lee, Juhwan
Abstract
In some embodiments, the present disclosure relates to a method that includes accessing data stored in an electronic memory. The data includes digitized imaging data from a segmented non-contrast computerized tomography (CT) image of an obstructive coronary artery disease (OCAD) patient. A plurality of assessment features are extracted from the data. The plurality of assessment features include image based features that characterize one or more of calcifications, fat tissue, heart structures, bone density, muscle, a lung, and breast tissue. The plurality of assessment features and a plurality of clinical factors are provided to a machine learning stage that is configured to generate a medical assessment corresponding to whether or not the OCAD patient would benefit from additional diagnostic tests to identify a presence and extent of the obstructive coronary artery disease.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
2.
NANOPARTICLE COMPOSITIONS CONTAINING SIRP-alpha siRNA FOR TREATMENT OF CANCER
Provided here are nanoparticle compositions containing siRNA to disrupt the signal regulatory protein-α (SIRPα) signaling pathway. Embodiments include methods for treating a subject diagnosed as having ovarian cancer by administering to the subject the nanoparticle composition containing SIRPα siRNA. Other methods include administering to the subject the nanoparticle composition containing SIRPα siRNA in addition to a platinum-based chemotherapeutic agent.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61P 35/04 - Antineoplastic agents specific for metastasis
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
Disclosed are antigen binding molecules that bind to Dickkopf-1 (DKK1) P20 peptide in the context of MHC-HLA-A2 (i.e., a DKK1-A2 complex). Such antigen binding molecules can by antibodies, antibody fragments, bi-specific antibodies, immunotoxins or the chimeric antigen receptor portion of a chimeric antigen receptor T cell. Also disclosed herein are methods of using said antigen binding molecules for the treatment of cancer.
Disclosed herein are kits of consumable parts for a closed-loop adipose transplant system, closed-loop adipose transplant systems, controllers therefor, and methods of use thereof.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A catheter control system may include a containment structure, a sensor coupled to the containment structure, and a plurality of actuators coupled to the containment structure. The containment structure may define a lumen configured to allow a fluid to flow therethrough, and a plurality of openings in fluid communication with the lumen. The sensor may be configured to detect a current position and/or orientation of the containment structure. Each of the actuators may be associated with at least one respective opening of the plurality of openings and configured to regulate fluid flow through the at least one respective opening.
Systems and methods for draining cerebrospinal fluid (CSF) are described herein described herein. In one implementation, an example system includes a signal generator, a plurality of electrodes operably connected to the signal generator, and a controller operably connected to the signal generator. The controller includes a processor and a memory. The controller is configured to deliver a neuromuscular electrical stimulation signal including at least one burst of pulses to at least one muscle in the subject's neck. The neuromuscular electrical stimulation signal is configured to induce a plurality of contractions of the at least one muscle. Additionally, the contractions of the at least one muscle are configured to squeeze at least one lymph node to create a pumping force, and the pumping force is configured to direct CSF flow in a proximal direction. The results in CSF drainage through the subject's neck lymphatic system.
A transcutaneous composition for treating an oxidative skin disorder of a mammal in need is disclosed containing an effective oxidative skin disorder treating amount of covalently-substituted oxidi zed activated charcoal (OACs) nanoparticles dissolved or dispersed in an aqueous composition containing a thickening agent providing a viscosity of about 1000 to about 20,000 cps, and about 5 to about 20 wt % of a skin permeation enhancer. A substituent of the substituted OAC comprises an average of about 2 to about 5 polyethylene glycol ( PEG) chains covalently linked to each OAC, or an average of about 2 to about 5 metal ion chelating groups covalently linked to each OAC, or an average of about 2 to about 5 PEG chains and an average of about 2 to about 5 metal ion chelating groups linked to each OAC. A method of treating an oxidative skin disorder of a mammal is also disclosed.
A61K 33/44 - Elemental carbon, e.g. charcoal, carbon black
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 39/06 - Free radical scavengers or antioxidants
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
An aortic graft removal device includes a cylindrical tubular body with a distal of a first diameter, a proximal opening, and a conduit between the distal and proximal openings. The conduit has a tapered throat constriction proximate to and smaller than to the distal opening. The device can have a plurality of rotating beads forming a leading edge to reduce shear forces on the endothelia lining. In operation, the device is inserted around an implanted aortic graft and advanced distally until the constriction in the conduit removes implanted hooks of the graft by displaying them radially inward as the construction moves around and, thereafter, enable the graft to be pulled proximally out of the device and/or aorta. Examples include a hinged design that splits the tubular body in half to enable clamshell closure around an implanted graft before the device is advanced along the graft to conduct a graft removal.
A61F 2/91 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
10.
METHODS FOR DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION
A method is disclosed of detecting a disease associated with pulmonary vascular remodeling in a subject. The method can comprise administering to the subject a compound of Formula I or Formula II. The method can further comprise imaging the compound in lungs of the subject using positron emission tomography to determine uptake of the compound in pulmonary vasculature of the lungs, wherein retention of the compound in the pulmonary vasculature reflects vascular remodeling. Methods of treating a disease associated with pulmonary vascular remodeling or for imaging a pulmonary vasculature in a subject are also provided.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
11.
BECLIN 2 AND USES THEREOF FOR TREATING CANCER AND NEURODEGENERATIVE DISEASES
Disclosed herein are recombinant proteins and/or polypeptides comprising a Beclin 2 polypeptide and/or a targeting moiety and methods relating to treating, preventing, reducing, and/or inhibiting a cancer, metastasis, and/or a neurodegenerative disease comprising administering said recombinant protein or polypeptides.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
Various implementations include a breast tissue expander device. The device includes a body and one or more tabs for coupling the device to a patient. The body has a first surface defining a convex surface, a second surface, a circumferential edge defined along an abutment of the first and second surfaces, a superior end, and an inferior end. A portion of the body has a maximum thickness of the body as measured between the first and second surfaces and is closer to the inferior end than to the superior end. Each of the one or more tabs has a first side, a second side, a first edge, and a second edge. The first edge of each tab is coupled to the body. At least one tab is coupled to the inferior end of the body. The at least one tab defines a total of two or more suture openings.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61M 27/00 - Drainage appliances for wounds, or the like
The present disclosure is directed to devices used for transplanting or recruiting cells, in addition to methods for making said devices and for using said devices in the treatment of medical disorders.
Described are methods for vascular regeneration m a subject with peripheral vascular disease. Described are also methods of treating a wound. The methods can include administering an effective amount of an O-glycnacylation modifier agent described here. The method increases O-glycnacylation level in the wound compared to O-glycnacylation level without administration of an effective amount of an O-glycnacylation modifier agent.
A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present disclosure relates to engineered nucleic acids that target CAG repeat sequences or viral polynucleotides. The present disclosure also relates to the uses of the engineered nucleic acids for treating polyglutamine diseases or a viral infection.
Disclosed herein are hydrogel devices and methods of making an use thereof. The devices can comprise: a continuous hydrogel matrix; a first chamber in the hydrogel matrix; and a second chamber in the hydrogel matrix; wherein the first chamber and the second chamber are each independently perfusable; wherein the first chamber is fluidly independent from the second chamber; wherein the first chamber is configured to be at least partially filled with adipose tissue; wherein the second chamber is configured to be at least partially filled with an oxygenated fluid; wherein the first chamber is defined by a first border; wherein the second chamber is defined by a second border; and wherein the first chamber and the second chamber are spaced apart from each other by an average distance of from 50 micrometers (microns, μm) to 800 μm as measured from the first border to the second border.
Disclosed herein are hydrogel devices and methods of making an use thereof. The devices can comprise: a continuous hydrogel matrix; a first chamber in the hydrogel matrix; and a second chamber in the hydrogel matrix; wherein the first chamber and the second chamber are each independently perfusable; wherein the first chamber is fluidly independent from the second chamber; wherein the first chamber is configured to be at least partially filled with adipose tissue; wherein the second chamber is configured to be at least partially filled with an oxygenated fluid; wherein the first chamber is defined by a first border; wherein the second chamber is defined by a second border; and wherein the first chamber and the second chamber are spaced apart from each other by an average distance of from 50 micrometers (microns, μm) to 800 μm as measured from the first border to the second border.
Devices and methods for controlling molecular transport are disclosed herein. The devices include a membrane having a plurality of nanochannels extending therethrough. The membrane has an inner electrically conductive layer and an outer dielectric layer. The outer dielectric layer creates an insulative barrier between the electrically conductive layer and the contents of the nanochannels. At least one electrical contact region is positioned on a surface of the membrane. The electrical contact region exposes the electrically conductive layer of the membrane for electrical coupling to external electronics. When the membrane is at a first voltage, molecules flow through the nanochannels at a first release rate. When the membrane is at a second voltage, charge accumulation within the nanochannels modulates the flow of molecules through the nanochannels to a second release rate that is different than the first release rate. Methods of fabricating devices for controlling molecular transport are also disclosed herein.
The present disclosure provides solid drug formulations, in particular to stabilized formulations of phosphonamidate-containing drugs, as well as methods for loading drug delivery devices with solid formulations.
A plug for coupling to a suture ring may include a distal portion extending from a distal end toward a proximal end of the plug, and a proximal portion coupled to the distal portion and extending from the proximal end toward the distal end of the plug. The distal portion may include a distal cylindrical body centered on a central axis of the plug and configured for being received at least partially within a central opening of the suture ring, and the distal cylindrical body may have a first outer diameter. The proximal portion may include a proximal cylindrical body centered on the central axis of the plug and configured for extending over a proximal end of the suture ring when the distal cylindrical body is received at least partially within the central opening of the suture ring, and the proximal cylindrical body may have a second outer diameter that is greater than the first outer diameter.
A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
Disclosed are compositions and methods for treating heart failure and cardiac damage that can lead to heart failure if left untreated comprising administering to a subject in need thereof a composition comprising an HSP60 derived peptide and an adjuvant.
By a Selective Elimination of Host Cells Capable of Producing HIV (SECH) approach, which includes a combination of latency reversal, blocking of new infections, inhibition of autophagy and induction of apoptosis, host cells harboring productive HIV infections can be cleared from a subject. Disclosed herein are methods for treating or inhibiting HIV in a subject, comprising a) reactivating latent HIV integrated into the genome of a cell infected with HIV in the subject, b) optionally administering to the subject an effective amount of a therapeutic agent to inhibit HIV infection, and c) administering to the subject an effective amount of a therapeutic agent to eliminate or reduce the number of cells containing replication-competent HIV. Kits for treating or inhibiting HIV in a subject are also disclosed.
Disclosed herein are kits of consumable parts for a closed-loop adipose transplant system, closed-loop adipose transplant systems, controllers therefor, and methods of use thereof.
Disclosed are antigen binding molecules that bind to Dickkopf-1 (DKK1) P20 peptide in the context of MHC-HLA-A2 (i.e., a DKK1-A2 complex). Such antigen binding molecules can by antibodies, antibody fragments, bi-specific antibodies, immunotoxins or the chimeric antigen receptor portion of a chimeric antigen receptor T cell. Also disclosed herein are methods of using said antigen binding molecules for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
28.
Automatic approach to establish dental occlusion for 1-piece, 2-piece, and 3-piece maxillary orthognathic surgeries
Methods and systems for establishing dental occlusion are described herein. These systems and methods can be used for 1-, 2-, or 3-piece maxillary orthognathic surgeries. An example computer-implemented method includes receiving a maxillary dental model and a mandibular dental model, identifying a plurality of dental landmarks in each of the maxillary and mandibular dental models, and extracting a plurality of points-of-interest from each of the maxillary and mandibular dental models. The dental landmarks include a plurality of maxillary dental landmarks and a plurality of mandibular dental landmarks. The method further includes aligning the maxillary and mandibular points-of-interest, and fine tuning the alignment of the maxillary and mandibular dental models to achieve maximum contact with a collision constraint.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
A61C 13/34 - Making or working of models, e.g. preliminary castings, trial denturesDowel pins
A61C 19/05 - Measuring instruments specially adapted for dentistry for determining occlusion
29.
SYSTEMS AND METHODS FOR IMPROVING CEREBROSPINAL FLUID (CSF) DRAINAGE
Systems and methods for draining cerebrospinal fluid (CSF) are described herein described herein. In one implementation, an example system includes a signal generator, a plurality of electrodes operably connected to the signal generator, and a controller operably connected to the signal generator. The controller includes a processor and a memory. The controller is configured to deliver a neuromuscular electrical stimulation signal including at least one burst of pulses to at least one muscle in the subject's neck. The neuromuscular electrical stimulation signal is configured to induce a plurality of contractions of the at least one muscle. Additionally, the contractions of the at least one muscle are configured to squeeze at least one lymph node to create a pumping force, and the pumping force is configured to direct CSF flow in a proximal direction. The results in CSF drainage through the subject's neck lymphatic system.
Disclosed are compositions and methods for identifying neoantigens and using neoantigens in the use of treating cancer, as well as autoimmune diseases, where antigens causing tissue destruction.
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12Q 1/6872 - Methods for sequencing involving mass spectrometry
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A catheter control system may include a containment structure, a sensor coupled to the containment structure, and a plurality of actuators coupled to the containment structure. The containment structure may define a lumen configured to allow a fluid to flow therethrough, and a plurality of openings in fluid communication with the lumen. The sensor may be configured to detect a current position and/or orientation of the containment structure. Each of the actuators may be associated with at least one respective opening of the plurality of openings and configured to regulate fluid flow through the at least one respective opening.
The present disclosure describes compositions for the treatment of oncological disorder, more particularly to amino acid polymer conjugates with platinum agents for the treatment of cancers.
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present disclosure is directed to a customizable distractor for oral and maxillofacial surgery and a system and method for designing and making the same. The distractor includes a steering apparatus that is movable along the helical-shaped distraction path to create gap between the first and second bone segments, an anchoring member for coupling the steering apparatus a first and second bone segment, and a distraction drive mechanism is used to drive movement of the steering apparatus along the distraction path.
A61B 17/66 - Compression or distraction mechanisms
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
36.
BECLIN 2 AND USES THEREOF FOR TREATING CANCER AND NEURODEGENERATIVE DISEASES
Disclosed herein are recombinant proteins and/or polypeptides comprising a Beclin 2 polypeptide and/or a targeting moiety and methods relating to treating, preventing, reducing, and/or inhibiting a cancer, metastasis, and/or a neurodegenerative disease comprising administering said recombinant protein or polypeptides.
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present disclosure is directed to devices used for transplanting or recruiting cells, in addition to methods for making said devices and for using said devices in the treatment of medical disorders.
The present disclosure is directed to devices used for transplanting or recruiting cells, in addition to methods for making said devices and for using said devices in the treatment of medical disorders.
Disclosed are methods and compositions for inhibiting IRF4 in T-cells, thereby improving transplant outcomes or treating an autoimmune disease such as a myelination disorder. Thus, disclosed are methods to improve a transplant outcome in a recipient of a transplant comprising inhibiting IRF4 in T-cells of the recipient, thereby improving the transplant outcome. In some embodiments, IRF4 can be inhibited by administering an IRF4 inhibitor (e.g., trametinib or anti-IRF4 siRNA), and/or by adoptive transfer of T-cells having IRF4 inhibition. In some embodiments, the T-cells are CD4+ Tcells, and the infiltration thereof into a transplant can be reduced. Also disclosed are methods of treating a subject with a myelination disorder (e.g., multiple sclerosis or encephalomyelitis) comprising inhibiting IRF4.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The present disclosure relates to engineered nucleic acids that target CAG repeat sequences or viral polynucleotides. The present disclosure also relates to the uses of the engineered nucleic acids for treating polyglutamine diseases or a viral infection.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Methods for probing the distribution and distance of the cell surface receptors and using the same to make multivalent ligands targeting said receptors are disclosed. Methods for making the multivalent ligands and detecting or imaging cells expressing receptors using the compounds are also provided.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Devices and methods for controlling molecular transport are disclosed herein. The devices include a membrane having a plurality of nanochannels extending therethrough. The membrane has an inner electrically conductive layer and an outer dielectric layer. The outer dielectric layer creates an insulative barrier between the electrically conductive layer and the contents of the nanochannels. At least one electrical contact region is positioned on a surface of the membrane. The electrical contact region exposes the electrically conductive layer of the membrane for electrical coupling to external electronics. When the membrane is at a first voltage, molecules flow through the nanochannels at a first release rate. When the membrane is at a second voltage, charge accumulation within the nanochannels modulates the flow of molecules through the nanochannels to a second release rate that is different than the first release rate. Methods of fabricating devices for controlling molecular transport are also disclosed herein.
An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
Disclosed herein are devices for use in transplanting cells. The devices can include a housing defining a cavity; and a support structure separating the cavity into a cell chamber and a reservoir chamber, wherein the support structure comprises a membrane for fluid communication between the cell chamber and reservoir chamber. The cell chamber can define a first opening comprising a microstructure containing an array of micro-channels, each having a diameter to facilitate growth of vascular tissues; and an array of micro-reservoirs, each having a diameter to facilitate housing of cell aggregates individually. The membrane can define a surface area that is at least 50% of a total surface area of the support structure. Methods of treating a subject for a disease condition, such as diabetes, are also disclosed.
By a Selective Elimination of Host Cells Capable of Producing HIV (SECH) approach, which includes a combination of latency reversal, blocking of new infections, inhibition of autophagy and induction of apoptosis, host cells harboring productive HIV infections can be cleared from a subject. Disclosed herein are methods for treating or inhibiting HIV in a subject, comprising a) reactivating latent HIV integrated into the genome of a cell infected with HIV in the subject, b) optionally administering to the subject an effective amount of a therapeutic agent to inhibit HIV infection, and c) administering to the subject an effective amount of a therapeutic agent to eliminate or reduce the number of cells containing replication-competent HIV. Kits for treating or inhibiting HIV in a subject are also disclosed.
The present disclosure provides solid drug formulations, in particular to stabilized formulations of phosphonamidate-containing drugs, as well as methods for loading drug delivery devices with solid formulations.
Disclosed are compositions and methods for treating heart failure and cardiac damage that can lead to heart failure if left untreated comprising administering to a subject in need thereof a composition comprising an HSP60 derived peptide and an adjuvant.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Methods and systems for establishing dental occlusion are described herein. These systems and methods can be used for 1-, 2-, or 3-piece maxillary orthognathic surgeries. An example computer-implemented method includes receiving a maxillary dental model and a mandibular dental model, identifying a plurality of dental landmarks in each of the maxillary and mandibular dental models, and extracting a plurality of points-of-interest from each of the maxillary and mandibular dental models. The dental landmarks include a plurality of maxillary dental landmarks and a plurality of mandibular dental landmarks. The method further includes aligning the maxillary and mandibular points-of-interest, and fine tuning the alignment of the maxillary and mandibular dental models to achieve maximum contact with a collision constraint.
Example neurostimulation induced medicine devices and methods of use are described herein. An example endotracheal device can include an elongate tubular member having a proximal end and a distal end, an inflatable cuff arranged between the proximal and distal ends of the elongate tubular member, and an electrode array disposed in proximity to an exterior surface of the inflatable cuff. The inflatable cuff can be configured to expand to contact a subject's tracheal wall. Additionally, the electrode array can include a plurality of flexible electrodes, where a set of the flexible electrodes anatomically align with a region of the subject's tracheal wall for selectively targeting vagus nerve activity.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
Inventor
Xia, James Jiong
Gateno, Jaime
Shen, Dinggang
Abstract
Systems and methods for estimating a patient-specific reference bone shape model for a patient with craniomaxillofacial (CMF) defects are described herein. An example method includes receiving a twodimensional ("2D") pre-trauma image of a subject, and generating a three-dimensional ("3D") facial surface model for the subject from the 2D pre-trauma image. The method also includes providing a correlation model between 3D facial and bone surfaces, and estimating a reference bone model for the subject using the 3D facial surface model and the correlation model.
The present disclosure is directed to a customizable distractor for oral and maxillofacial surgery and a system and method for designing and making the same. The distractor includes a steering apparatus that is movable along the helical-shaped distraction path to create gap between the first and second bone segments, an anchoring member for coupling the steering apparatus a first and second bone segment, and a distraction drive mechanism is used to drive movement of the steering apparatus along the distraction path.
A61B 17/66 - Compression or distraction mechanisms
A61B 17/58 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements
The exemplified system and method facilitate an objective, non-invasive measurement of myelin quality and integrity in living brains based on isolation of myelin-specific magnetic relaxation constants in k-space. The system uses magnetic resonance (MR) signals to select signatures specific to, or associated with, myelin and its structure and to then encode the selected signatures into an image or model to which the quantitative myelin health information can be co-registered with 2D, 3D visualization, and tractography of the myelin-signal isolated MR information. The system also sets a model for digital hierarchical learning of biomedical signals in MR, and beyond, based on experimental data in which it executes the herein described signal isolation operations.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01N 24/00 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
G01R 33/20 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance
53.
CANCER NEOANTIGENS AND THEIR UTILITIES IN CANCER VACCINES AND TCR-BASED CANCER IMMUNOTHERAPY
Disclosed are compositions and methods for identifying neoantigens and using neoantigens in the use of treating cancer, as well as autoimmune diseases, where antigens causing tissue destruction.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Disclosed are methods and compositions for inhibiting IRF4 in T-cells, thereby improving transplant outcomes or treating an autoimmune disease such as a myelination disorder. Thus, disclosed are methods to improve a transplant outcome in a recipient of a transplant comprising inhibiting IRF4 in T-cells of the recipient, thereby improving the transplant outcome. In some embodiments, IRF4 can be inhibited by administering an IRF4 inhibitor (e.g., trametinib or anti-IRF4 siRNA), and/or by adoptive transfer of T-cells having IRF4 inhibition. In some embodiments, the T-cells are CD4+ Tcells, and the infiltration thereof into a transplant can be reduced. Also disclosed are methods of treating a subject with a myelination disorder (e.g., multiple sclerosis or encephalomyelitis) comprising inhibiting IRF4.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
55.
IRF-4 ENGINEERED T CELLS AND USES THEREOF IN TREATING CANCER
Methods to treat cancer in a subject comprising administering to the subject a therapeutically effective amount of T-cells of the subject having increased IRF4 polypeptide expression compared to a control are disclosed. Also disclosed are methods of increasing tumor reactivity of a T-cell by increasing IRF4 polypeptide expression, and methods to predict the likelihood that a subject having cancer will respond therapeutically to administered T-cells having increased IRF4 polypeptide expression. Also disclosed are compositions comprising a T-cell and a viral vector encoding an IRF4 polypeptide. The compositions are methods are useful for treating numerous cancers in which higher level expression of IRF4 in T-cells would be beneficial. In some embodiments, activated tumorspecific T-cells having increased IRF4 expression have greater infiltration in tumors and enhanced local immunological responses.
Example neurostimulation induced medicine devices and methods of use are described herein. An example endotracheal device can include an elongate tubular member having a proximal end and a distal end, an inflatable cuff arranged between the proximal and distal ends of the elongate tubular member, and an electrode array disposed in proximity to an exterior surface of the inflatable cuff. The inflatable cuff can be configured to expand to contact a subject's tracheal wall. Additionally, the electrode array can include a plurality of flexible electrodes, where a set of the flexible electrodes anatomically align with a region of the subject's tracheal wall for selectively targeting vagus nerve activity.
The invention relates to a method for feeding in electrical power by means of a wind power system comprising at least one wind farm into an electrical supply grid, at a grid connection point, the electrical supply grid having at least one distribution grid and at least one further higher portion of the grid, lying hierarchically above the distribution grid, and the grid connection point being connected to the distribution grid, wherein the method comprises in some embodiments increasing an initial feed-in limitation with respect to the grid connection point.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
Disclosed herein are devices for use in transplanting cells. The devices can include a housing defining a cavity; and a support structure separating the cavity into a cell chamber and a reservoir chamber, wherein the support structure comprises a membrane for fluid communication between the cell chamber and reservoir chamber. The cell chamber can define a first opening comprising a microstructure containing an array of micro-channels, each having a diameter to facilitate growth of vascular tissues; and an array of micro-reservoirs, each having a diameter to facilitate housing of cell aggregates individually. The membrane can define a surface area that is at least 50% of a total surface area of the support structure. Methods of treating a subject for a disease condition, such as diabetes, are also disclosed.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
59.
TAU PHOSPHORYLATION INHIBITORS AND METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE
The present disclosure relates to compounds that are useful as tau phosphorylation inhibitors. Further disclosed are compounds and methods for treating or preventing Alzheimer's disease.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Systems and methods for orthognathic surgical planning are described herein. An example computer-implemented method can include generating a composite three-dimensional (3D) model of a subject's skull, defining a global reference frame for the composite 3D model, performing a cephalometric analysis on the composite 3D model to quantify at least one geometric property of the subject's skull, performing a virtual osteotomy to separate the composite 3D model into a plurality of segments, performing a surgical simulation using the osteotomized segments, and designing a surgical splint or template for the subject.
A61B 6/14 - Applications or adaptations for dentistry
A61C 7/00 - Orthodontics, i.e. obtaining or maintaining the desired position of teeth, e.g. by straightening, evening, regulating, separating, or by correcting malocclusions
A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereonDental implantsImplanting tools
Disclosed herein are methods for scoring a patient on a liver transplant list, methods of performing a liver transplant, methods of determining expected post-transplant mortality in a subject, and methods of determining expected sepsis. The disclosed methods can be used to avoid futile transplantation, avoid wasting organs, and promote efficient management of organ placement. These methods involve assaying a sample from the subject for T cell receptor (TCR) repertoire.
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
G06F 19/22 - for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or Single-Nucleotide Polymorphism [SNP] discovery or sequence alignment
63.
INDUCTION OF SENESCENCE USING PROTON PUMP INHIBITORS
Provided herein are proton pump inhibitors that promote cellular senescence, methods of using the proton pump inhibitors to promote cellular senescence and compositions and kits comprising the proton pump inhibitors. Also provided are methods of screening for candidate agents that promote senescence or inhibit senescence.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
64.
SYSTEM AND METHOD USING CARDIAC-ESOPHAGEAL IMPEDANCE MAPPING TO PREDICT AND DETECT ESOPHAGEAL INJURY DURING CARDIAC ABLATION PROCEDURES
Exemplified methods and apparatus use assess electrical coupling between an ablative catheter and the esophagus using measurements of electrical impedance to beneficially predict esophageal damage prior to ablation and to detect on-going esophageal damage during ablation. The technology facilitates the determination of regional variations of electrical coupling between the esophagus and the ablation catheter to infer the risk of the esophagus and its nearby structures.
Disclosed is a method for rejuvenating cells, such as chondrocytes, that involves contacting the cell with a composition comprising a synthetic ribonucleic acid comprising at least one modified nucleoside encoding a telomerase reverse transcriptase, and a composition comprising an anti-inflammatory agent, in amounts effective to extend at least one telomere in the cell.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
Disclosed are compositions and methods for electroporation that provide for high payload of a therapeutic agent into a cell. Electroporation buffer solutions comprising a plurality of buffering agents, at least one salt, a carbon polyol, and optionally an acid, wherein the plurality of buffering agents and acid are in an amount such that the pH of the electroporation buffer solution is from about 4.5 to about 5 are disclosed. Kits comprising the electroporation buffer solutions, and optionally a therapeutic agent, are also disclosed. Methods of introducing doxorubicin into immune cells to form a cellular vector, using the electroporation buffer solutions, and compositions produced therefrom are also described. The compositions comprising the cellular vectors can be used to treat a cancerous tissue in a subject, such as the lungs.
Compounds that target vascular endothelial growth factor receptors for therapy and imaging are disclosed. Methods for making the compounds and detecting or imaging cells expressing VEGFR using the compounds are also provided. In accordance with the purposes of the disclosed subject matter, as embodied and broadly described herein, disclosed are compounds, and methods of making and using the compounds. The disclosed compounds, in one aspect, are quinazoline compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
Compounds that target vascular endothelial growth factor receptors for therapy and imaging are disclosed. Methods for making the compounds and detecting or imaging cells expressing VEGFR using the compounds are also provided. In accordance with the purposes of the disclosed subject matter, as embodied and broadly described herein, disclosed are compounds, and methods of making and using the compounds. The disclosed compounds, in one aspect, are quinazoline compounds.
pH-sensitive fluorescent compounds that can generate a detectable signal for the relatively small changes in proton concentration associated with cancerous tissue are described. Methods of making and using the compounds to help detect cancerous tissue are also disclosed.
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
C09B 23/12 - Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being branched
Provided herein are polypeptides that are selectively cleaved by cathepsin E. Also provided are methods of detecting cathepsin E. The methods comprise contacting cathepsin E with the polypeptides provided herein and detecting fluorescence. Further provided are methods of diagnosing cancer or pre-cancerous conditions in a subject. Also provided herein is a multilayered nanoparticle or a composition comprising the multilayer nanoparticle, wherein the multilayered nanoparticle comprises a negatively charged nanoparticle core or capsule coated with alternating positive and negative layers. Optionally, the positive layer comprises a positively charged protease degradable polypeptide. Optionally, the negative layer comprises a negatively charged therapeutic agent or a therapeutic agent and a means for providing the agent with a negative charge. For example, optionally, the therapeutic agent is linked to a negatively charged polymer. Further provided are methods of treating or preventing a disease characterized by expression of a protease in a subject using the nanoparticle.
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
Provided herein are polypeptides that are selectively cleaved by cathepsin E. Also provided are methods of detecting cathepsin E. The methods comprise contacting cathepsin E with the polypeptides provided herein and detecting fluorescence. Further provided are methods of diagnosing cancer or pre-cancerous conditions in a subject. Also provided herein is a multilayered nanoparticle or a composition comprising the multilayer nanoparticle, wherein the multilayered nanoparticle comprises a negatively charged nanoparticle core or capsule coated with alternating positive and negative layers. Optionally, the positive layer comprises a positively charged protease degradable polypeptide. Optionally, the negative layer comprises a negatively charged therapeutic agent or a therapeutic agent and a means for providing the agent with a negative charge. For example, optionally, the therapeutic agent is linked to a negatively charged polymer. Further provided are methods of treating or preventing a disease characterized by expression of a protease in a subject using the nanoparticle.
Systems, methods, and apparatuses for generating and using representations of individual or aggregate human medical data Invention includes a computer system comprising a processor, a database that stores a plurality of patient medical data, a virtual patient module, and a device to display an image of the virtual patient to a user.
G06Q 50/00 - Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
patents
